Biocon gains on inaugurating first U.S. manufacturing facility in New Jersey
Biocon is currently trading at Rs. 366.70, up by 2.75 points or 0.76% from its previous closing of Rs. 363.95 on the BSE.
The scrip opened at Rs. 364.20 and has touched a high and low of Rs. 369.00 and Rs. 364.20 respectively. So far 8331 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 405.90 on 18-Jul-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 370.75 and Rs. 353.15 respectively. The current market cap of the company is Rs. 49313.90 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.86% and 16.68% respectively.
Biocon has inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI). Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over $30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline.
This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint. The Cranbury facility represents a strategic advancement for the company’s U.S. operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the United States.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
